India, March 20 -- NATCO Pharma announced the launch of Semaglutide Injection (multi dose vials) in India market tomorrow on Day 1 of patent expiry.NATCO received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February'26 for multi dose vials and pen device based on the clinical comparison study. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.NATCO plans to launch Semaglutide injection in the form of multi dose vials of strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml under the brand names SEMANATTM and SEMAFULLTM. Multi dose vials will be launched at MRP of INR 1,290 per month for ...